Aliases & Classifications for Plague

MalaCards integrated aliases for Plague:

Name: Plague 12 76 59 43 3 15 73
Yersiniosis 59 3
Yersinia Infections 73

Characteristics:

Orphanet epidemiological data:

59
plague
Prevalence: 1-9/100000 (Europe); Age of onset: All ages;

Classifications:

Orphanet: 59  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:3482
ICD10 33 A20 A20.9
ICD9CM 35 020 020.9
MeSH 44 D010930
NCIt 50 C85015
Orphanet 59 ORPHA707
MESH via Orphanet 45 D010930 D015009
UMLS via Orphanet 74 C0032064 C0043407
ICD10 via Orphanet 34 A20.0 A20.1 A20.2 more

Summaries for Plague

MedlinePlus : 43 Plague is an infection caused by the bacterium Yersinia pestis. The bacteria are found mainly in rats and in the fleas that feed on them. People and other animals can get plague from rat or flea bites. In the past, plague destroyed entire civilizations. Today plague is uncommon, due to better living conditions and antibiotics. There are three forms of plague: Bubonic plague causes the tonsils, adenoids, spleen, and thymus to become inflamed. Symptoms include fever, aches, chills, and tender lymph glands. In septicemic plague, bacteria multiply in the blood. It causes fever, chills, shock, and bleeding under the skin or other organs. Pneumonic plague is the most serious form. Bacteria enter the lungs and cause pneumonia. People with the infection can spread this form to others. This type could be a bioterror agent. Lab tests can diagnose plague. Treatment is a strong antibiotic. There is no vaccine. NIH: National Institute of Allergy and Infectious Diseases

MalaCards based summary : Plague, also known as yersiniosis, is related to bubonic plague and septicemic plague, and has symptoms including fever and pruritus. An important gene associated with Plague is CCR5 (C-C Motif Chemokine Receptor 5 (Gene/Pseudogene)), and among its related pathways/superpathways are Influenza A and Kaposi's sarcoma-associated herpesvirus infection. The drugs Anticholesteremic Agents and Antimetabolites have been mentioned in the context of this disorder. Affiliated tissues include lymph node, vasculature or and lung, and related phenotypes are cellular and cardiovascular system

Disease Ontology : 12 A primary bacterial infectious disease that results in infection, located in lymph node, located in vasculature or located in lungs, has material basis in Yersinia pestis, which is transmitted by oriental rat flea (Xenopsylla cheopis) infected by feeding on rodents and other mammals, transmitted by air, transmitted by direct contact or transmitted by ingestion of contaminated undercooked food.

CDC : 3 Plague is a disease that affects humans and other mammals. It is caused by the bacterium, Yersinia pestis. Humans usually get plague after being bitten by a rodent flea that is carrying the plague bacterium or by handling an animal infected with plague. Plague is infamous for killing millions of people in Europe during the Middle Ages. Today, modern antibiotics are effective in treating plague. Without prompt treatment, the disease can cause serious illness or death. Presently, human plague infections continue to occur in the western United States, but significantly more cases occur in parts of Africa and Asia.

Wikipedia : 76 Plague is an infectious disease caused by the bacterium Yersinia pestis. Symptoms include fever,... more...

Related Diseases for Plague

Diseases related to Plague via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Related Disease Score Top Affiliating Genes
1 bubonic plague 34.0 CCR5 PLG
2 septicemic plague 33.7 MYD88 PLG
3 pneumonic plague 33.3 PLG SULT1A2
4 tularemia 11.3
5 anthrax disease 10.9
6 exanthema subitum 10.3 CD83 CD86
7 mucocutaneous leishmaniasis 10.3 CCR5 TLR9
8 immune-complex glomerulonephritis 10.3 CCR5 TLR9
9 pulmonary vein stenosis 10.2 PECAM1 TYMP
10 blastic plasmacytoid dendritic cell 10.2 MYD88 PECAM1
11 toxoplasmosis 10.1 CCR5 MYD88 TLR9
12 myositis fibrosa 10.1 CD86 MYD88 TLR9
13 hydrocele 10.1 PECAM1 SELE
14 viral infectious disease 10.1 CCR5 DDX58 TLR9
15 aging 10.0
16 cholera 10.0
17 ecthyma 9.9
18 typhoid fever 9.9
19 pneumonia 9.9
20 influenza 9.9
21 smallpox 9.9
22 legionnaire disease 9.8
23 malaria 9.8
24 legionnaires' disease 9.8
25 relapsing fever 9.8
26 measles 9.8
27 behcet syndrome 9.8 CCR5 SELE TLR9
28 hemangioendothelioma 9.8 PECAM1 PLG
29 chronic myocardial ischemia 9.8 PLG TYMP
30 endophthalmitis 9.7 PLG SELE
31 yellow fever 9.7 CCR5 TLR9
32 diabetes mellitus, noninsulin-dependent 9.7
33 motion sickness 9.7
34 hemochromatosis, type 1 9.7
35 macular degeneration, age-related, 1 9.7
36 crohn's disease 9.7
37 hepatitis 9.7
38 laryngotracheitis 9.7
39 swine influenza 9.7
40 mucositis 9.7
41 q fever 9.7
42 bartonellosis 9.7
43 dysentery 9.7
44 blastomycosis 9.7
45 scrub typhus 9.7
46 schistosomiasis 9.7
47 hantavirus pulmonary syndrome 9.7
48 impotence 9.7
49 leptospirosis 9.7
50 ischemia 9.7

Graphical network of the top 20 diseases related to Plague:



Diseases related to Plague

Symptoms & Phenotypes for Plague

UMLS symptoms related to Plague:


fever, pruritus

MGI Mouse Phenotypes related to Plague:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.11 CCR5 CD86 CDC25C DDX58 MGAT1 MYD88
2 cardiovascular system MP:0005385 10.01 CCR5 CD83 MGAT1 MYD88 PECAM1 PLG
3 digestive/alimentary MP:0005381 9.92 PLG PTS TLR9 CCR5 CDC25C DDX58
4 hematopoietic system MP:0005397 9.85 CCR5 CD83 CD86 DDX58 MGAT1 MYD88
5 endocrine/exocrine gland MP:0005379 9.8 CD83 CD86 CDC25C MGAT1 MYD88 PLG
6 homeostasis/metabolism MP:0005376 9.7 PLG PTS SELE TLR9 TYMP CCR5
7 immune system MP:0005387 9.32 CCR5 CD83 CD86 DDX58 MYD88 PECAM1

Drugs & Therapeutics for Plague

Drugs for Plague (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 186)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Anticholesteremic Agents Phase 4
2 Antimetabolites Phase 4,Phase 3,Phase 2,Early Phase 1
3 Calcium, Dietary Phase 4,Phase 3
4 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2
5 Hypolipidemic Agents Phase 4
6 Lipid Regulating Agents Phase 4
7 Rosuvastatin Calcium Phase 4 147098-20-2
8 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
9 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
10 Adjuvants, Immunologic Phase 4,Phase 2,Phase 3,Phase 1
11 Aluminum phosphate Phase 4,Not Applicable
12 Antacids Phase 4,Phase 1
13 Anti-Ulcer Agents Phase 4,Phase 1
14 Gastrointestinal Agents Phase 4,Phase 3,Phase 1
15 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Antibiotics, Antitubercular Phase 4,Not Applicable
17 Acidophilus Nutraceutical Phase 4,Not Applicable
18
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
19
Ofloxacin Approved Phase 3 82419-36-1 4583
20
Streptomycin Approved, Vet_approved Phase 2, Phase 3 57-92-1 19649
21
Oseltamivir Approved Phase 3,Phase 2 204255-11-8, 196618-13-0 65028
22
Dimethyl sulfoxide Approved, Vet_approved Phase 3 67-68-5 679
23
Etanercept Approved, Investigational Phase 3 185243-69-0
24
Morphine Approved, Investigational Phase 3 57-27-2 5288826
25
Interferon beta-1a Approved, Investigational Phase 2, Phase 3 145258-61-3 6438354
26
Apremilast Approved, Investigational Phase 3 608141-41-9 11561674
27
Crizotinib Approved Phase 3,Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
28
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
29
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 446556 60843
30
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 498142 38904
31
Etoposide Approved Phase 3,Phase 1,Phase 2,Early Phase 1 33419-42-0 36462
32
Benzocaine Approved, Investigational Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
33
Epinephrine Approved, Vet_approved Phase 2, Phase 3,Not Applicable 51-43-4 5816
34
Racepinephrine Approved Phase 2, Phase 3,Not Applicable 329-65-7 838
35
Methotrexate Approved Phase 3,Phase 2,Early Phase 1 1959-05-2, 59-05-2 126941
36
rituximab Approved Phase 3,Phase 1,Phase 2 174722-31-7 10201696
37
Cytarabine Approved, Investigational Phase 3,Early Phase 1 147-94-4 6253
38
Pimavanserin Approved, Investigational Phase 3,Phase 2 706779-91-1 16058810
39
Rivaroxaban Approved Phase 3 366789-02-8
40
Adalimumab Approved Phase 3 331731-18-1 16219006
41
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
42
Pembrolizumab Approved Phase 3 1374853-91-4
43 Vedolizumab Approved Phase 3 943609-66-3
44
Pregabalin Approved, Illicit, Investigational Phase 3 148553-50-8 5486971
45
Dimethyl fumarate Approved, Investigational Phase 3 624-49-7 5271565 637568
46
Dalteparin Approved Phase 3 9005-49-6
47 Edoxaban Approved Phase 3 480449-70-5
48
Enoxaparin Approved Phase 3 9005-49-6 772
49 Fondaparinux Approved, Investigational Phase 3 104993-28-4
50
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594

Interventional clinical trials:

(show top 50) (show all 125)
# Name Status NCT ID Phase Drugs
1 Resuvastatin Treatment for Symptomatic Middle Cerebral Artery Stenosis Based on High-resolution Magnetic Resonance Imaging Unknown status NCT02041117 Phase 4 Rosuvastatin
2 Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine in Adults and Elderly Persons Completed NCT01404182 Phase 4
3 Evaluation of Long-term Prucalopride Treatment With Chronic Constipation in Subjects Aged ≥ 18 Years Completed NCT01424228 Phase 4 placebo;prucalopride
4 EASY: Extended Access to Sollpura Over Years Completed NCT02823964 Phase 4 Liprotamase
5 Lactobacillus Reuteri DSM 17938 in the Prevention of Antibiotic-associated Diarrhea in Children: Protocol of a Randomized Controlled Trial Completed NCT02871908 Phase 4 Lactobacillus reuteri DSM 17938;Placebo
6 School Inner-City Asthma Intervention Study (SICAS-2) Recruiting NCT02291302 Phase 4
7 Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections Unknown status NCT01978938 Phase 3 Eravacycline;Levofloxacin
8 Treatment and Diagnosis of Plague Completed NCT00128466 Phase 2, Phase 3 gentamicin;streptomycin
9 Mouse Allergen and Asthma Intervention Trial Completed NCT01251224 Phase 3
10 Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications Completed NCT02949011 Phase 3 Baloxavir Marboxil;Placebo to Baloxavir Marboxil;Oseltamivir;Placebo to Oseltamivir
11 A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension Completed NCT00644605 Phase 3 sildenafil;sildenafil;placebo;sildenafil
12 SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis Completed NCT02279498 Phase 3 Liprotamase;porcine (pig) PERT
13 Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy Completed NCT00676507 Phase 3
14 A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations Completed NCT02413580 Phase 3
15 Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects Completed NCT02378506 Phase 3
16 Phase 3 Study of RPC1063 in Relapsing MS Completed NCT02294058 Phase 3 RPC1063;Beta interferon
17 Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study) Completed NCT02047734 Phase 2, Phase 3 RPC1063 0.5 mg;RPC1063 1 mg;RPC1063 placebo;Interferon β-1a;IFN β-1a placebo
18 PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Completed NCT01212757 Phase 3 Apremilast 20mg;Apremilast 30mg;Placebo + 20 mg Apremilast;Placebo + 30 mg Apremilast
19 Study Evaluating Persistence of Anti-HBs Antibodies in Uraemic Patients Receiving Henogen's HBV Vaccine, or Fendrix™ Completed NCT00445185 Phase 3
20 A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to GSK Biologicals Adjuvanted Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Have Not Been Exposed to Hepatitis B. Completed NCT00291941 Phase 3
21 LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy Completed NCT01523587 Phase 3 afatinib;erlotinib
22 An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene Completed NCT00932893 Phase 3 PF-02341066;Pemetrexed;Docetaxel
23 Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia Recruiting NCT03121586 Phase 3 Pimavanserin
24 Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1) Recruiting NCT02970292 Phase 3 Pimavanserin;Placebo
25 A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients Recruiting NCT02111564 Phase 3 Rivaroxaban, 10 mg;Rivaroxaban, 7.5 mg;Placebo
26 A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug Recruiting NCT03104400 Phase 3 Adalimumab;ABT-494;Placebo for ABT-494;Placebo for Adalimumab
27 A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) Recruiting NCT03066778 Phase 3 Normal saline solution;Carboplatin;Cisplatin;Etoposide
28 A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s) Recruiting NCT03162796 Phase 3 Guselkumab;Placebo
29 A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) Recruiting NCT03114657 Phase 3 Crenezumab;Placebo
30 Vedolizumab Subcutaneous Long-Term Open-Label Extension Study Recruiting NCT02620046 Phase 3 Vedolizumab SC
31 Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 Recruiting NCT02403323 Phase 3 etrolizumab
32 A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants With Moderately to Severely Active Crohn's Disease (CD) Recruiting NCT02394028 Phase 3 Etrolizumab;Placebo
33 A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors Recruiting NCT02165215 Phase 3 Etrolizumab;Placebo
34 Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies Recruiting NCT02118584 Phase 3 Etrolizumab
35 A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors Recruiting NCT02100696 Phase 3 Etrozulimab;Placebo
36 A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures. Recruiting NCT01747915 Phase 3 Pregabalin Dose Level 1;Pregabalin Dose Level 2;Placebo
37 Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®) Recruiting NCT02907177 Phase 3 Ponesimod
38 A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clon Recruiting NCT01463306 Phase 3 Pregabalin
39 Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE) Recruiting NCT02798471 Phase 3 Edoxaban;Standard of Care
40 Hydrocortisone Treatment In Systemic Low Blood Pressure During Hypothermia in Asphyxiated Newborns Active, not recruiting NCT02700828 Phase 2, Phase 3 Hydrocortisone;Placebo
41 A Study to Compare ABT-494 Monotherapy to Methotrexate Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate Active, not recruiting NCT02706873 Phase 3 ABT-494 matching placebo;Methotrexate;Methotrexate matching placebo;ABT-494
42 A Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate Active, not recruiting NCT02629159 Phase 3 Placebo for Adalimumab;ABT-494;Adalimumab;Placebo for ABT-494
43 Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC Active, not recruiting NCT03260894 Phase 3 Pembrolizumab;Epacadostat;Sunitinib;Pazopanib
44 Study to Assess if ABP798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Rituximab Active, not recruiting NCT02792699 Phase 3 ABP 798;Rituximab
45 (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive Active, not recruiting NCT02039726 Phase 3 Quizartinib;Salvage Chemotherapy
46 RESULT: Reliable, Emergent Solution Using Liprotamase Treatment Active, not recruiting NCT03051490 Phase 3 Liprotamase;porcine PERT
47 A Study Comparing ABT-494 Monotherapy to Methotrexate (MTX) Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY) Active, not recruiting NCT02706951 Phase 3 Methotrexate;ABT-494;ABT-494 matching placebo;Methotrexate matching placebo
48 Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis Active, not recruiting NCT02611830 Phase 3 Vedolizumab IV 300 mg;Placebo IV;Vedolizumab SC 108 mg;Placebo SC
49 Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease Active, not recruiting NCT02611817 Phase 3 Vedolizumab SC 108 mg;Placebo;Vedolizumab IV 300 mg
50 Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS) Active, not recruiting NCT02239120 Phase 3 optional ASA as comedication;placebo to ASA;placebo to optional ASA as comedication;placebo to dabigatran etexilate;ASA 100 mg;dabigatran etexilate

Search NIH Clinical Center for Plague

Genetic Tests for Plague

Anatomical Context for Plague

The Foundational Model of Anatomy Ontology organs/tissues related to Plague:

19
Lymph Node, Vasculature Or

MalaCards organs/tissues related to Plague:

41
Lung, Lymph Node, Testes, Spleen, Skin, Thymus, Tonsil

Publications for Plague

Articles related to Plague:

(show top 50) (show all 949)
# Title Authors Year
1
The Deer Mouse (Peromyscus maniculatus) as an Enzootic Reservoir of Plague in California. ( 29700709 )
2018
2
Reemergence of human plague in Yunnan, China in 2016. ( 29897940 )
2018
3
Plague disease model with weather seasonality. ( 29800562 )
2018
4
Of mice and men: Traces of life in the death registries of the 1630 plague in Milano. ( 29305937 )
2018
5
The 2017 plague outbreak in Madagascar: Data descriptions and epidemic modelling. ( 29866421 )
2018
6
Plague: Bridging gaps towards better disease control. ( 29773334 )
2018
7
Fumigating the Hygienic Model City: Bubonic Plague and the Sulfurozador in Early-Twentieth-Century Buenos Aires. ( 29886876 )
2018
8
Human case of bubonic plague resulting from the bite of a wild Gunnison's prairie dog during translocation from a plague-endemic area. ( 29110441 )
2018
9
Mixed pneumonic plague and nosocomial MDR-bacterial infection of lung: a rare case report. ( 29843675 )
2018
10
Phylogeny and Classification of <i>Yersinia pestis</i> Through the Lens of Strains From the Plague Foci of Commonwealth of Independent States. ( 29887859 )
2018
11
Six Whole-Genome Assemblies of Yersinia pestis subsp. microtus bv. ulegeica (Phylogroup 0.PE5) Strains Isolated from Mongolian Natural Plague Foci. ( 29930050 )
2018
12
Nine Whole-Genome Assemblies of<i>Yersinia pestis</i>subsp.<i>microtus</i>bv. Altaica Strains Isolated from the Altai Mountain Natural Plague Focus (No. 36) in Russia. ( 29348336 )
2018
13
An Evaluation of Removal Trapping to Control Rodents Inside Homes in a Plague-Endemic Region of Rural Northwestern Uganda. ( 29768127 )
2018
14
A historical evaluation of Chinese tongue diagnosis in the treatment of septicemic plague in the pre-antibiotic era, and as a new direction for revolutionary clinical research applications. ( 29691189 )
2018
15
The Resistance to Plague Infection among<i>Meriones persicus</i>from Endemic and Non-endemic Regions in Iran: The Role of Gut Microbiota. ( 29318122 )
2018
16
Simultaneous immunodetection of anthrax, plague and tularemia from blood cultures utilizing multiplexed suspension arrays. ( 29386263 )
2018
17
Human ectoparasites and the spread of plague in Europe during the Second Pandemic. ( 29339508 )
2018
18
Detecting plague-host abundance from space: Using a spectral vegetation index to identify occupancy of great gerbil burrows. ( 29399006 )
2018
19
Impact of Sylvatic Plague Vaccine on Non-target Small Rodents in Grassland Ecosystems. ( 29744628 )
2018
20
New genotyping method for the causative agent of crayfish plague (Aphanomyces astaci) based on whole genome data. ( 29953875 )
2018
21
Identifying the social and environmental determinants of plague endemicity in Peru: insights from a case study in Ascope, La Libertad. ( 29409470 )
2018
22
Ecologic Features of Plague Outbreak Areas, Democratic Republic of the Congo, 2004-2014. ( 29350136 )
2018
23
Depletion of Glucose Activates Catabolite Repression during Pneumonic Plague. ( 29555700 )
2018
24
One year immunogenicity and safety of subunit plague vaccine in Chinese healthy adults: An extended open-label study. ( 29927704 )
2018
25
Madagascar can build stronger health systems to fight plague and prevent the next epidemic. ( 29300731 )
2018
26
Hidden sites in the distribution of the crayfish plague pathogen Aphanomyces astaci in Eastern Europe: Relicts of genetic groups from older outbreaks? ( 29787742 )
2018
27
Plague in Madagascar - A Tragic Opportunity for Improving Public Health. ( 29261403 )
2018
28
Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia. ( 29725025 )
2018
29
Pneumonic plague epidemic in Northeast China in 1910-1911: Dr. Wu Lien-Teh's epidemic preventive system for plague control. ( 29372498 )
2018
30
Investigation of Pneumonic Plague, Madagascar. ( 29260670 )
2018
31
Humoral and cellular immune responses to Yersinia pestis Pla antigen in humans immunized with live plague vaccine. ( 29889829 )
2018
32
Molecular epidemiological investigations of plague in Eastern Province of Zambia. ( 29433443 )
2018
33
Inhalational Gentamicin Treatment Is Effective Against Pneumonic Plague in a Mouse Model. ( 29740404 )
2018
34
Analysis of 3800-year-old Yersinia pestis genomes suggests Bronze Age origin for bubonic plague. ( 29884871 )
2018
35
Plague in Madagascar. ( 29316870 )
2018
36
<i>Plica polonica</i>: from national plague to death of the disease in the nineteenth-century Vilnius. ( 29798937 )
2018
37
SCIENTISTS and SCIENCE ADVOCATES: Dr. Younes Karimi (1929-2008), the Prominent Iranian Physician in the Field of Plague and Other Infectious Diseases ( 29380589 )
2018
38
The Forgotten Plague: Psychiatric Manifestations of Ebola, Zika, and Emerging Infectious Diseases. ( 29302150 )
2017
39
Characterization of duck plague virus stability at extreme conditions of temperature, pH and salt concentration. ( 27746073 )
2017
40
Small-Scale Die-Offs in Woodrats Support Long-Term Maintenance of Plague in the U.S. Southwest. ( 28792853 )
2017
41
An Epidemic, a Scourge, or a Plague. ( 29323816 )
2017
42
Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague. ( 28220110 )
2017
43
Vaccines for Conservation: Plague, Prairie Dogs &amp;amp; Black-Footed Ferrets as a Case Study. ( 28879613 )
2017
44
Temporal phylogeography of Yersinia pestis in Madagascar: Insights into the long-term maintenance of plague. ( 28873412 )
2017
45
Comparison of Zoonotic Bacterial Agents in Fleas Collected from Small Mammals or Host-Seeking Fleas from a Ugandan Region Where Plague Is Endemic. ( 29276773 )
2017
46
Protein abundances can distinguish between naturally-occurring and laboratory strains of Yersinia pestis, the causative agent of plague. ( 28854255 )
2017
47
Plague: A Millenary Infectious Disease Reemerging in the XXI Century. ( 28904964 )
2017
48
RNA-seq comparative analysis of Peking ducks spleen gene expressionA 24A h post-infected with duck plague virulent or attenuated virus. ( 28903751 )
2017
49
Cake culture continues to plague office workers. ( 29269922 )
2017
50
Paleoproteomics of the Dental Pulp: The plague paradigm. ( 28746380 )
2017

Variations for Plague

Expression for Plague

Search GEO for disease gene expression data for Plague.

Pathways for Plague

Pathways related to Plague according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.36 DDX58 MYD88 PLG TLR9
2
Show member pathways
12.08 CCR5 CD86 DDX58 MYD88
3 11.87 CD83 DDX58 MYD88 PECAM1 TLR9
4 11.66 CD86 PECAM1 SELE
5 10.88 MYD88 SELE TLR9
6 10.61 MYD88 PECAM1 SELE TLR9

GO Terms for Plague

Biological processes related to Plague according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.71 CCR5 CD86 CDC25C DDX58
2 inflammatory response GO:0006954 9.56 CCR5 MYD88 SELE TLR9
3 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.49 MYD88 TLR9
4 response to interleukin-1 GO:0070555 9.48 MYD88 SELE
5 positive regulation of interleukin-8 production GO:0032757 9.46 DDX58 TLR9
6 leukocyte cell-cell adhesion GO:0007159 9.43 PECAM1 SELE
7 positive regulation of interferon-beta production GO:0032728 9.37 DDX58 TLR9
8 positive regulation of interleukin-10 production GO:0032733 9.32 CD83 TLR9
9 toll-like receptor 9 signaling pathway GO:0034162 9.16 MYD88 TLR9
10 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 8.96 DDX58 TLR9
11 positive regulation of interleukin-6 production GO:0032755 8.8 DDX58 MYD88 TLR9

Molecular functions related to Plague according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 coreceptor activity GO:0015026 8.96 CCR5 CD86
2 interleukin-1 receptor binding GO:0005149 8.62 MYD88 TLR9

Sources for Plague

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....